Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Authors

Philippe Moreau

Published

April 27, 2016

Abstract

Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.

Supporters

Support the authors with ResearchCoin

Journal

New England Journal of Medicine

Topics

DOI

10.1056/nejmoa1516282

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Authors

Philippe Moreau

Published

April 27, 2016

Abstract

Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.

Supporters

Support the authors with ResearchCoin

Journal

New England Journal of Medicine

Topics

DOI

10.1056/nejmoa1516282

Paper

Paper

Paper

Paper

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Abstract

Supporters

Journal

Topics

DOI

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Abstract

Supporters

Journal

Topics

DOI